UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-based physician group in Central New Jersey, implemented UltraSPECT’s Xpress3.Cardiac solution at four of their sites.

July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states, Puerto Rico, and the District of Columbia to help reduce the risks for heart attacks and strokes among millions of Medicare fee-for-service beneficiaries.

CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning Device for heart failure. Patients have been treated in more than 15 countries, including patients in key international markets where the device is commercially available, and patients enrolled in PARACHUTE IV, the company’s U.S. pivotal trial under investigational device exemption (IDE).

People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a recent study in the Journal of the American College of Cardiology.

bioresorbable stent, bioabsorbable stent, Absorb BVS, visualizing bioresorbable stents
Absorb, imaging bioresorbable stent, BVS under angiography
Absorb, bioresorbable stent, BVS
imaging the BVS, imaging bioresorbable stents
Absorb, imaging bioresorbable stent, BVS under angiography
Absorb, imaging bioresorbable stent, IVUS, Volcano, coronary lesion
SJM, OCT, Optical coherence tomography, Bioresorbable stent, BVS
Bioresorbable stent on IVUS, BVS on IVUS, imaging bioresorbable stents, Absorb

Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of interventional cardiology. These novel devices follow the successive evolutions of angioplasty, bare metal stents (BMS) and drug-eluting stents (DES), each of which led to a marked improvement in clinical outcomes for patients suffering from coronary artery disease (CAD). The most exciting aspect of BRS is preliminary data shows the vessel is healing, and histologically looks nearly normal approximately three years after scaffold implantation.

July 21, 2016 — A new paper published in the June issue of Computer cautions that while mobile health (mHealth) is poised for a boom, greater privacy and security measures are needed to realize the full benefits of the technology.

European Symposium on the New Agreed Draft Regulations on Medical Devices

World Cardiac Surgery and Angiology Conference

A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart predicted outcomes of mitral valve surgery in some heart failure patients. The study was published in JACC: Basic to Translational Science.

New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment of functional (secondary) mitral regurgitation (FMR).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now